The agency first approved Kymriah in August 2017 to treat patients age 25 or younger with acute lymphoblastic leukemia. Clinicians may now also use the therapy to treat patients with large B-cell lymphoma whose cancer has progressed after at least two previous therapies.
The new approval allows Kymriah to directly compete with Gilead Sciences’ cell therapy Yescarta, which is also indicated to treat patients with large B-cell lymphoma, reports Reuters.
Kymriah, administered as a one-time treatment, will cost $373,000 — the same price as Yescarta.
More articles on supply chain:
McKesson adds Medtronic exec as independent director: 4 takeaways
FDA approves first drug for rare form of rickets: 3 things to know
Ascension forms global supply chain company with Australian hospital operator: 8 things to know
